These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

648 related articles for article (PubMed ID: 34968414)

  • 1. The CRISPR-Cas toolbox and gene editing technologies.
    Liu G; Lin Q; Jin S; Gao C
    Mol Cell; 2022 Jan; 82(2):333-347. PubMed ID: 34968414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Implications of CRISPR-Cas9 Genome Editing for IR.
    Perkons NR; Sheth R; Ackerman D; Chen J; Saleh K; Hunt SJ; Nadolski GJ; Shi J; Gade TP
    J Vasc Interv Radiol; 2018 Sep; 29(9):1264-1267.e1. PubMed ID: 30146193
    [No Abstract]   [Full Text] [Related]  

  • 3. RNA-Targeting CRISPR-Cas Systems and Their Applications.
    Burmistrz M; Krakowski K; Krawczyk-Balska A
    Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32046217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ji Luo Elucidates the CRISPR Gene Editing Technology, and How It May Affect Cancer Therapy in the Future.
    Luo J
    Oncology (Williston Park); 2016 Oct; 30(10):879. PubMed ID: 27753053
    [No Abstract]   [Full Text] [Related]  

  • 5. [Research advances on the development and application of clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein system].
    Tan JJ; Peng YZ; Huang GT
    Zhonghua Shao Shang Za Zhi; 2021 Jul; 37(7):681-687. PubMed ID: 34304411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRISPR technologies for bacterial systems: Current achievements and future directions.
    Choi KR; Lee SY
    Biotechnol Adv; 2016 Nov; 34(7):1180-1209. PubMed ID: 27566508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CRISPR technology: The engine that drives cancer therapy.
    Zhang M; Eshraghian EA; Jammal OA; Zhang Z; Zhu X
    Biomed Pharmacother; 2021 Jan; 133():111007. PubMed ID: 33227699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Could CRISPR be the solution for gene editing's Gordian knot?
    Fang H; Wang W
    Cell Biol Toxicol; 2016 Dec; 32(6):465-467. PubMed ID: 27614448
    [No Abstract]   [Full Text] [Related]  

  • 9. Characterization and applications of Type I CRISPR-Cas systems.
    Hidalgo-Cantabrana C; Barrangou R
    Biochem Soc Trans; 2020 Feb; 48(1):15-23. PubMed ID: 31922192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genome editing using CRISPR, CAST, and Fanzor systems.
    Song B; Bae S
    Mol Cells; 2024 Jul; 47(7):100086. PubMed ID: 38909984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineered miniature CRISPR-Cas system for mammalian genome regulation and editing.
    Xu X; Chemparathy A; Zeng L; Kempton HR; Shang S; Nakamura M; Qi LS
    Mol Cell; 2021 Oct; 81(20):4333-4345.e4. PubMed ID: 34480847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Toolkit of CRISPR-Based Genome Editing Systems in Drosophila.
    Xu J; Ren X; Sun J; Wang X; Qiao HH; Xu BW; Liu LP; Ni JQ
    J Genet Genomics; 2015 Apr; 42(4):141-9. PubMed ID: 25953352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repurposing type I-F CRISPR-Cas system as a transcriptional activation tool in human cells.
    Chen Y; Liu J; Zhi S; Zheng Q; Ma W; Huang J; Liu Y; Liu D; Liang P; Songyang Z
    Nat Commun; 2020 Jun; 11(1):3136. PubMed ID: 32561716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Expanding Class 2 CRISPR Toolbox: Diversity, Applicability, and Targeting Drawbacks.
    Hajizadeh Dastjerdi A; Newman A; Burgio G
    BioDrugs; 2019 Oct; 33(5):503-513. PubMed ID: 31385197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRISPR/Cas System: Recent Advances and Future Prospects for Genome Editing.
    Manghwar H; Lindsey K; Zhang X; Jin S
    Trends Plant Sci; 2019 Dec; 24(12):1102-1125. PubMed ID: 31727474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in CRISPR-based genome editing technology and its applications in cardiovascular research.
    Li ZH; Wang J; Xu JP; Wang J; Yang X
    Mil Med Res; 2023 Mar; 10(1):12. PubMed ID: 36895064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-CRISPR protein applications: natural brakes for CRISPR-Cas technologies.
    Marino ND; Pinilla-Redondo R; Csörgő B; Bondy-Denomy J
    Nat Methods; 2020 May; 17(5):471-479. PubMed ID: 32203383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CRISPR/Cas: a Nobel Prize award-winning precise genome editing technology for gene therapy and crop improvement.
    Li C; Brant E; Budak H; Zhang B
    J Zhejiang Univ Sci B; 2021 Apr; 22(4):253-284. PubMed ID: 33835761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diversification of the CRISPR Toolbox: Applications of CRISPR-Cas Systems Beyond Genome Editing.
    Balderston S; Clouse G; Ripoll JJ; Pratt GK; Gasiunas G; Bock JO; Bennett EP; Aran K
    CRISPR J; 2021 Jun; 4(3):400-415. PubMed ID: 34152221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CRISPR-Cas12a System for Biosensing and Gene Regulation.
    Shi Y; Fu X; Yin Y; Peng F; Yin X; Ke G; Zhang X
    Chem Asian J; 2021 Apr; 16(8):857-867. PubMed ID: 33638271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.